Genome Interpretation, Nanoparticles, Gene Therapy, 2024 IPOs; Nautilus Biotechnology
Touching Base · Genetic Engineering & Biotechnology News (GEN)
Audio is streamed directly from the publisher (sphinx.acast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Episode 7 (February 2, 2024): Simplify Genomics launches genome interpretation platform, COUR’s nanoparticles for autoimmunity, gene replacement therapy for heart condition, CG Oncology and ArriVent IPOs; an interview with Nautilus Biotechnology co-founders, Sujal Patel and Parag Mallick.
Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:
Human Longevity Spin-Out Aims to Tap into Variant Interpretation Market
By Uduak Thomas, GEN, January 31st, 2024
Light My Fire: COUR Raises $105M Series A to Advance Tolerogenic Nanoparticles for Autoimmunity
By Jonathan Grinstein, GEN Edge, January 30th, 2024
Gene Replacement Therapy Halts Fatal Arrhythmogenic Condition in Mice
GEN, January 30th, 2024
StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M
By Alex Philippidis, GEN Edge, January 28th, 2024
Hosted on Acast. See acast.com/privacy for more information.